Stockscreener 앱 받기
47.25
0.92%
0.43
전일 마감가:
$46.82
열려 있는:
$47.01
하루 거래량:
167.85K
Relative Volume:
0.79
시가총액:
$882.62M
수익:
$299.77M
순이익/손실:
$364.23M
주가수익비율:
2.5239
EPS:
18.7211
순현금흐름:
$79.27M
1주 성능:
-3.02%
1개월 성능:
+6.51%
6개월 성능:
+47.38%
1년 성능:
+68.09%
1일 변동 폭
$47.01
$48.52
1주일 범위
$46.37
$50.49
52주 변동 폭
$24.95
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
47.25 | 882.62M | 299.77M | 364.23M | 79.27M | 18.72 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Australia
Reasons Why Investors Should Consider Betting on Arvinas Stock - Zacks Investment Research
Rigel Pharmaceuticals Inc. Research & Ratings | RI2 - Barron's
Rigel Pharmaceuticals Inc. Research & Ratings | RI2 - Barron's
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance UK
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
18 new employees at Rigel receive stock awards vesting over four years. - Stock Titan
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate - GlobeNewswire Inc.
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow (NASDAQ:RIGL) 2026-09-15 - Seeking Alpha
Rigel Pharmaceuticals at Cantor conference: veppanu launch leads growth push - Investing.com Nigeria
Rigel Pharmaceuticals at Cantor conference: veppanu launch leads growth push By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals at Cantor conference: veppanu launch leads growth push - Investing.com Canada
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $85 - Moomoo
Trading the Move, Not the Narrative: (RIGL) Edition - Stock Traders Daily
EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K - Benzinga
Rigel (NASDAQ: RIGL) CCO now holds 61,622 shares - Stock Titan
Rigel Pharmaceuticals (RIGL) CEO returns 2,424 shares to issuer - Stock Titan
Rigel Pharmaceuticals (NASDAQ: RIGL) insider now holds 50,559 shares - Stock Titan
Rigel Pharmaceuticals CFO to present at three m... - Pluang
Rigel to Participate in Upcoming September Investor Conferences - PR Newswire
Rigel Pharmaceuticals Inc. (RIGL) Peer Comparison – Compare with Others - Value Research
Rigel (RIGL) Results Breakdown: EPS Exceeds Its Estimate for the Current Session; Market Reaction: Shares Finish 3.64% Down in Latest TradingSurprise Factor Analysis - Vinanet
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research - MarketBeat
Rigel Pharmaceuticals (RIGL) Institutional Ownership 2026 $RIGL - MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for RIGL - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) (Q2 2026) Earnings Call Highlig - GuruFocus
RIGL Maintains Neutral Rating -- Price Target Raised to $49.00 b - GuruFocus
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $49 - Moomoo
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope - Yahoo Finance
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
(RIGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85 - GuruFocus
Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A - Stock Titan
Rigel announces availability of Veppanu in the USA - The Pharma Letter
Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico - marketscreener.com
Rigel Pharmaceuticals (RIGL): Soleus Capital group discloses 9.9% ownership stake - Stock Titan
Rigel's VEPPANU Is Now Available for Certain Advanced Breast Cancers - Stock Titan
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer - PR Newswire
Rigel (RIGL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) Stock News Today - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Issues Pessimistic Estimate for RIGL Earnings - MarketBeat
Pacer Advisors Inc. Purchases 48,882 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Cantor Fitzgerald Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $43 - 富途牛牛
HC Wainwright Issues Pessimistic Forecast for RIGL Earnings - MarketBeat
Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts - simplywall.st
Rigel Pharmaceuticals in-licenses Veppanu, targ... - Pluang
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rigel Pharmaceuticals 주식 (RIGL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ali-Jackson Kamil | Director |
Jun 22 '26 |
Sale |
35.00 |
2,500 |
87,500 |
10,125 |
| Ali-Jackson Kamil | Director |
Jun 22 '26 |
Proposed Sale |
35.00 |
2,500 |
87,500 |
0 |
| Schorno Dean L | EVP & Chief Financial Officer |
Jun 01 '26 |
Option Exercise |
14.83 |
3,381 |
50,139 |
79,718 |
| Ali-Jackson Kamil | Director |
May 26 '26 |
Sale |
29.17 |
2,500 |
72,925 |
12,625 |
| Ali-Jackson Kamil | Director |
May 26 '26 |
Proposed Sale |
29.17 |
2,500 |
72,925 |
0 |
| MOOS WALTER H | Director |
Feb 20 '26 |
Option Exercise |
24.00 |
4,000 |
96,000 |
16,722 |
| MOOS WALTER H | Director |
Feb 20 '26 |
Sale |
36.36 |
4,000 |
145,440 |
12,722 |
| MOOS WALTER H | Director |
Feb 20 '26 |
Proposed Sale |
36.36 |
4,000 |
145,440 |
0 |
| RODRIGUEZ RAUL R | CEO, President |
Jan 26 '26 |
Option Exercise |
27.40 |
80,000 |
2,192,000 |
285,243 |
| Schorno Dean L | EVP & Chief Financial Officer |
Dec 22 '25 |
Option Exercise |
21.51 |
6,500 |
139,786 |
64,235 |
4.19%
2.91%
자본화:
|
볼륨(24시간):